Your browser doesn't support javascript.
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection.
Tut, Gokhan; Lancaster, Tara; Butler, Megan S; Sylla, Panagiota; Spalkova, Eliska; Bone, David; Kaur, Nayandeep; Bentley, Christopher; Amin, Umayr; Jadir, Azar T; Hulme, Samuel; Ayodel, Morenike; Dowell, Alexander C; Pearce, Hayden; Zuo, Jianmin; Margielewska-Davies, Sandra; Verma, Kriti; Nicol, Samantha; Begum, Jusnara; Jinks, Elizabeth; Tut, Elif; Bruton, Rachel; Krutikov, Maria; Shrotri, Madhumita; Giddings, Rebecca; Azmi, Borscha; Fuller, Chris; Irwin-Singer, Aidan; Hayward, Andrew; Copas, Andrew; Shallcross, Laura; Moss, Paul.
  • Tut G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. g.tut@bham.ac.uk.
  • Lancaster T; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Butler MS; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Sylla P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Spalkova E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bone D; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Kaur N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bentley C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Amin U; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Jadir AT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Hulme S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Ayodel M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Dowell AC; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Pearce H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Zuo J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Margielewska-Davies S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Verma K; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Nicol S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Begum J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Jinks E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Tut E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bruton R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Krutikov M; UCL Institute of Health Informatics, London, UK.
  • Shrotri M; UCL Institute of Health Informatics, London, UK.
  • Giddings R; UCL Institute of Health Informatics, London, UK.
  • Azmi B; UCL Institute of Health Informatics, London, UK.
  • Fuller C; UCL Institute of Health Informatics, London, UK.
  • Irwin-Singer A; Department of Health and Social Care, London, UK.
  • Hayward A; Health Data Research UK, London, UK.
  • Copas A; UCL Institute for Global Health, London, UK.
  • Shallcross L; UCL Institute of Health Informatics, London, UK.
  • Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. p.moss@bham.ac.uk.
Nat Aging ; 2(6): 536-547, 2022 06.
Article in English | MEDLINE | ID: covidwho-2186114
ABSTRACT
We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Nat Aging Year: 2022 Document Type: Article Affiliation country: S43587-022-00224-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Language: English Journal: Nat Aging Year: 2022 Document Type: Article Affiliation country: S43587-022-00224-w